Express Scripts Holding Co

Latest stories

22h
Morningstar
China Stocks In Focus After Ringing In 'Year Of The Monkey'While U.S. traders enjoy the President's Day holiday on Monday, they'll be keep
China Stocks In Focus After Ringing In 'Year Of The Monkey'
Morningstar / Posted 22 hours ago
While U.S. traders enjoy the President's Day holiday on Monday, they'll be keeping a cautious eye on the reopening of markets in mainland China following a week-long Lunar New Year holiday celebrating the Year of the Monkey. Caution is required... Read more
3d
The Arizona Republic
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
The Arizona Republic / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
WLBZ Bangor
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
WLBZ Bangor / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
WKYC Cleveland
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
WKYC Cleveland / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
WZZM 13 Grand Rapids
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
WZZM 13 Grand Rapids / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
First Coast News
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
First Coast News / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
KTVB Boise
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
KTVB Boise / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
WFAA Dallas-Fort Worth
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
WFAA Dallas-Fort Worth / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
WGRZ-TV Buffalo
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
WGRZ-TV Buffalo / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
KREM.com Spokane
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
KREM.com Spokane / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
3d
WCSH 6 Portland
Lobbyists turn their attention to state capitalsDebbie Mann pays more than $3,800 out of pocket each year for the prescription
Lobbyists turn their attention to state capitals
WCSH 6 Portland / Posted 3 days ago
Debbie Mann pays more than $3,800 out of pocket each year for the prescription drug Enbrel to banish the stabbing pain that rheumatoid arthritis causes in her joints. Mann would love a cheaper form of the medicine, but it’s not yet sold in the U.S.... Read more
10 related stories
4d
Morningstar
CVS Gets Boost From Prescription-Drug SalesThe quarter was broadly in line with Wall Street expectations, as CVS drugstore
CVS Gets Boost From Prescription-Drug Sales
Morningstar / Posted 4 days ago
The quarter was broadly in line with Wall Street expectations, as CVS drugstores and its big pharmacy-benefits management business continued to cover more patients and dispense more drugs. On Tuesday, CVS shares rose nearly 1% to $90.51. The... Read more
11d
Canberra Times
Turing's Martin Shkreli shows unwelcome mirror to pharma industryShkreli has become the Wolf of Pharma Street - he's basically come to represent
Turing's Martin Shkreli shows unwelcome mirror to pharma industry
Canberra Times / Posted 11 days ago
Shkreli has become the Wolf of Pharma Street - he's basically come to represent everything that was bad and wrong with pharma. But his strategy of finding an old drug, raising its price, and taking the profit is one that's increasingly common among... Read more
354 related stories
11d
The Age
Turing's Martin Shkreli shows unwelcome mirror to pharma industryShkreli has become the Wolf of Pharma Street - he's basically come to represent
Turing's Martin Shkreli shows unwelcome mirror to pharma industry
The Age / Posted 11 days ago
Shkreli has become the Wolf of Pharma Street - he's basically come to represent everything that was bad and wrong with pharma. But his strategy of finding an old drug, raising its price, and taking the profit is one that's increasingly common among... Read more
354 related stories
11d
Sydney Morning Herald
Turing's Martin Shkreli shows unwelcome mirror to pharma industryShkreli has become the Wolf of Pharma Street - he's basically come to represent
Turing's Martin Shkreli shows unwelcome mirror to pharma industry
Sydney Morning Herald / Posted 11 days ago
Shkreli has become the Wolf of Pharma Street - he's basically come to represent everything that was bad and wrong with pharma. But his strategy of finding an old drug, raising its price, and taking the profit is one that's increasingly common among... Read more
354 related stories
16d
Channel NewsAsia
Express Scripts drops coverage of Valeant diabetes drug GlumetzaNEW YORK: Express Scripts Holding Co, the U.S. No. 1 pharmacy benefits manager,
Express Scripts drops coverage of Valeant diabetes drug Glumetza
Channel NewsAsia / Posted 16 days ago
NEW YORK: Express Scripts Holding Co, the U.S. No. 1 pharmacy benefits manager, said on Friday it would stop covering Glumetza, a diabetes drug made by Valeant Pharmaceuticals International Inc, after a generic competitor enters the market on Feb.... Read more
3 related stories
16d
Channel NewsAsia
Payers see price leverage with entry of Merck hepatitis C drugREUTERS: U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's n
Payers see price leverage with entry of Merck hepatitis C drug
Channel NewsAsia / Posted 16 days ago
REUTERS: U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers. The Food and Drug Administration on Thursday approved Merck's Zepatier for treatment... Read more
16 related stories
16d
FOX News
FDA approves Merck's new hepatitis C pillU.S. regulators on Thursday approved a new once-daily treatment for the liver-d
FDA approves Merck's new hepatitis C pill
FOX News / Posted 16 days ago
U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc. The Food and Drug Administration approved the drug, Zepatier, with or without the older antiviral drug ribavirin, for... Read more
16 related stories
16d
Channel NewsAsia
FDA approves Merck's new hepatitis C pillREUTERS: U.S. regulators on Thursday approved a new once-daily pill for the liv
FDA approves Merck's new hepatitis C pill
Channel NewsAsia / Posted 16 days ago
REUTERS: U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors. The list price for Zepatier will be... Read more
16 related stories
16d
Channel NewsAsia
US FDA approves Merck's new hepatitis C pillREUTERS: U.S. regulators on Thursday approved a new once-daily treatment for th
US FDA approves Merck's new hepatitis C pill
Channel NewsAsia / Posted 16 days ago
REUTERS: U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc. The Food and Drug Administration approved the drug, Zepatier, with or without the older antiviral drug... Read more
24d
Business Insurance
Compounding pharmacies take on Express ScriptsCompounding pharmacies believe that Express Scripts Inc. worked to “significant
Compounding pharmacies take on Express Scripts
Business Insurance / Posted 24 days ago
Compounding pharmacies believe that Express Scripts Inc. worked to “significantly eliminate their revenue” and “drive them out of the marketplace” by limiting reimbursements and fulfillment of prescription compounded drugs, a plaintiff attorney... Read more
25d
Business Insurance
Compounding pharmacies sue Express Scripts over 'boycott'Six compounding pharmacies have sued Express Scripts Inc. in federal court, all
Compounding pharmacies sue Express Scripts over 'boycott'
Business Insurance / Posted 25 days ago
Six compounding pharmacies have sued Express Scripts Inc. in federal court, alleging in the antitrust suit that the St. Louis-based pharmacy benefit manager conspired with other PBMs to drive compounding pharmacies out of the market. Express... Read more
30d
Swissinfo
When New Cancer Treatments Fail, Italy Wants Its Money Back(Bloomberg) -- When trying new cancer treatments, Italy’s state-run health serv
When New Cancer Treatments Fail, Italy Wants Its Money Back
Swissinfo / Posted 30 days ago
(Bloomberg) -- When trying new cancer treatments, Italy’s state-run health service is demanding a money-back guarantee. The experiment is being monitored in the U.S. and across Europe, making a country better known for its fashion and fettuccine a... Read more

People in this news